PUBLISHER: IMARC | PRODUCT CODE: 1541385
PUBLISHER: IMARC | PRODUCT CODE: 1541385
The global epigenetics market size reached US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 12.6% during 2024-2032.
Epigenetics refers to the study of heritable changes in the expression of active and inactive genes. The sources of changes can be both external from environmental factors or internal factors, such as age and disease. It is commonly used for the diagnosis of underlying conditions and preventing them from getting transferred to the future generations. It involves the use of various enzymes, instruments, such as sequencers, spectrometers and sonicators, reagents and kits. They are commonly utilized for deoxyribonucleic acid (DNA) and histone methylation, non-coding ribonucleic acid (RNA), acetylation and phosphorylation. As a result, epigenetics is widely used for the diagnosis, monitoring and treatment of oncological, autoimmune, metabolic, cardiovascular and pain disorders.
The increasing prevalence of cancer and autoimmune deficiency syndrome (AIDS) across the globe is among the key factors driving the market growth. Moreover, the widespread adoption of epigenetic solutions for non-oncological ailments is providing a thrust to the market growth. The sudden outbreak of the coronavirus disease (COVID-19) is also providing growth opportunities to market players. For instance, various research institutes are running advanced epigenetic tests to study the impact of the virus on the human genome and are developing tools for early recognition, risk evaluations and developing personalized treatments. Additionally, the development of DNA and RNA modifying enzymes, such as acetylases, methyltransferases, reverse transcriptase and ligases, and the launch of highly sensitive and selective tests and instruments, are acting as other growth-inducing factors. These innovations facilitate the assessment of locus-specific DNA methylation on a genome. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global epigenetics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, technology, and application.
Reagents
Kits
Chip Sequencing Kit
Whole Genomic Amplification Kit
Bisulfite Conversion Kit
RNA Sequencing Kit
Others
Instruments
Enzymes
Services
DNA Methylation
Histone Methylation
Histone Acetylation
Large Non-Coding RNA
MicroRNA Modification
Chromatin Structures
Oncology
Solid Tumors
Liquid Tumors
Non-Oncology
Inflammatory Diseases
Metabolic Diseases
Infectious Diseases
Cardiovascular Diseases
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Active Motif Inc., Agilent Technologies Inc., Diagenode Diagnostics (Hologic Inc), Illumina Inc., Merck KGaA, PerkinElmer Inc., Roche Holding AG, Thermo Fisher Scientific Inc. and Zymo Research Corporation.